Key Findings From Recent Trials

Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU).
• Brand Names Available In United Kingdom: Adrucil, generic injectable supplies and topical generics are commonly used; availability of specific brands (Efudex/Efudix equivalents, Fluoroplex, Actikerall) varies by Trust and supplier.
• ATC Code: L01BC02 (Antineoplastic agents → Antimetabolites → Pyrimidine analogues).
• Forms & Dosages: Injection vials (250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL); topical creams and lotions 0.5%, 1%, 2%, 4%, 5% in 20–40 g tubes and solutions.
• Manufacturers In United Kingdom: Not specified in the product data; multiple international manufacturers supply the UK market (Teva, Mylan/Viatris, Sandoz, Pfizer, Medac).
• Registration Status In United Kingdom: Prescription only; topical and IV formulations are licensed and used within NHS formularies and supplied under MHRA regulation.
• OTC / Rx Classification: Prescription only (Rx) in all formulations.

Major 2022–2025 Studies

Worried whether recent trials change how 5‑FU is used in dermatology or oncology?

Recent systematic reviews and meta‑analyses from 2022–2025 prioritise topical 5‑FU versus alternative field therapies for actinic keratosis, showing consistently higher lesion clearance at 12–24 weeks.

Evidence indicates topical 5‑FU creams (1–5%) clear more lesions and give better field cancerisation control than single‑lesion treatments such as cryotherapy in many pooled analyses.

Durability of response is frequently reported out to 12 months in these reviews, supporting topical 5‑FU as a field treatment for AK.

In systemic oncology settings, pooled analyses reaffirm that 5‑FU remains a backbone cytotoxic agent for colorectal regimens, usually given with leucovorin or combined with oxaliplatin.

These oncology analyses report improved overall survival when 5‑FU is included as part of multiagent protocols compared with older single‑agent approaches.

Trials from 2023 that examined infusion versus bolus schedules further confirm regimen‑dependent toxicity profiles and efficacy trade‑offs.

Safety signals in the period emphasise DPYD‑related risk and the value of pre‑emptive genotyping for high‑dose systemic use.

Clinicians in dermatology still favour topical 5‑FU for field cancerisation where cosmetic outcome and long‑term clearance are priorities.

Keywords that clinicians search for include 5‑FU trials 2023, topical 5‑FU AK efficacy and 5‑FU meta‑analysis when reviewing the literature.

Main Outcomes

What did reviewers find about effectiveness?

Topical use: higher complete clearance rates and better control of field cancerisation versus lesion‑directed therapy.

Systemic use: established activity in colorectal, gastric and certain breast cancers when combined in multiagent regimens.

Oncology endpoints reported improved progression and overall survival metrics in pooled datasets where 5‑FU was a core component.

Safety Observations

Concerned about toxicity and genetic risk?

Topical 5‑FU predicts consistent local dermatologic reactions such as erythema, crusting and desquamation; systemic absorption is limited for routine dermatology use.

Systemic toxicities cluster around myelosuppression, mucositis and gastrointestinal adverse events and correlate strongly with DPYD deficiency.

European guidance increasingly recommends DPYD genotyping and pre‑emptive dose adjustment when high‑dose systemic schedules are planned.

Overall, monitoring strategies have been refined in practice to reduce avoidable severe reactions.

Clinical Mechanism Of Action

Layman’s Explanation

Want a simple explanation of how fluorouracil works?

Fluorouracil (5‑FU) stops rapidly dividing cells from making the DNA and RNA they need to reproduce.

Applied to the skin as a cream, it selectively damages sun‑damaged cells that make up actinic keratoses, prompting inflammation and eventual clearance.

Given intravenously, it disrupts tumour cell replication throughout the body, which is why it is widely used in systemic oncology.

Scientific Breakdown

Curious about the chemistry behind the effect?

5‑FU is a pyrimidine analogue that is metabolised inside cells to active metabolites: fluorodeoxyuridine monophosphate (FdUMP) and fluorouridine triphosphate (FUTP).

FdUMP forms a stable complex with thymidylate synthase and folinic acid derivatives, blocking deoxythymidine monophosphate (dTMP) synthesis and causing “thymineless death.”

FUTP can be misincorporated into RNA, interrupting RNA processing and function, which contributes to cytotoxicity.

Metabolism & Pharmacogenetics

Worried about inherited risk factors?

5‑FU is catabolised primarily by dihydropyrimidine dehydrogenase (DPD), encoded by DPYD.

DPYD deficiency increases the risk of severe systemic toxicity with IV or high‑exposure schedules.

Topical application gives limited systemic exposure and a much lower risk of DPYD‑related reactions, but large treated areas still warrant caution.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Wondering what 5‑FU is licensed for in the UK?

In the United Kingdom, fluorouracil is a prescription‑only medicine available in topical strengths from 0.5% to 5% and in IV formulations.

Topical creams (Efudix equivalents and generics) are standard NHS dermatology options for actinic keratosis and superficial basal cell carcinoma.

Intravenous 5‑FU (Adrucil and generics) is included in systemic oncology protocols for colorectal, gastric and certain breast cancers and appears under ATC L01BC02.

Local NHS Trust formularies determine which brands and presentations are stocked and supplied to clinics.

Notable Off‑Label Trends

Curious what clinicians sometimes do beyond the licence?

Off‑label use includes low‑concentration field therapy regimens and combination topical strategies, such as sequential imiquimod followed by 5‑FU in specialist centres.

Adapted topical schedules are sometimes used in organ transplant recipients to manage extensive field change under specialist supervision.

Intralesional or modified topical schedules are occasional options in specialist dermatology but require documented risk/benefit and close monitoring.

Dosage Strategy

General Dosing

Need a quick guide to usual doses?

Topical preparations are commonly prescribed as 0.5–5% creams applied once or twice daily to lesions or a field for 2–6 weeks, depending on formulation and site.

Injectable 5‑FU is supplied in vial strengths such as 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL and is administered within protocolised oncology regimens.

Expect progressive local inflammation with topical therapy; that response is a sign the medicine is working.

Condition‑Specific Dosing

What does a clinician typically order for cancer or dermatology?

For colorectal or gastrointestinal oncology a sample regimen from product information is bolus IV 12 mg/kg/day (maximum 800 mg/day) for 4 days followed by 6 mg/kg every other day for six doses (maximum 400 mg/day), though local protocols vary.

Dermatology regimens for AK or superficial BCC commonly direct cream application 1–2 times daily for 2–6 weeks or until the lesion resolves.

Dose Modification Considerations

Afraid of the wrong dose in frail patients?

Adjustments are required for severe hepatic impairment, significant renal disease, elderly frailty and where DPYD variants are identified.

Pediatric use is specialist only, and the drug is contraindicated in pregnancy due to teratogenicity.

Safety Protocols

Contraindications

Unsure whether someone should not receive 5‑FU?

Absolute contraindications include known hypersensitivity to fluorouracil or excipients, pregnancy, severe bone marrow suppression, or uncontrolled active infection.

Relative contraindications include significant hepatic or renal impairment, severe cardiac disease and poor nutritional state; clinical judgement is required.

All forms are prescription‑only and require informed counselling about expected effects and risks.

Adverse Effects

Worried about what side effects look like?

Systemic (IV) toxicities commonly include myelosuppression, mucositis, nausea, vomiting, diarrhoea, alopecia and photosensitivity; infusion schedules determine severity.

Topical use predictably causes local erythema, crusting, burning and desquamation at the application site and limited systemic absorption in standard use.

Monitoring blood counts, liver function and hydration is essential for systemic schedules in routine oncology practice.

Interaction Mapping

Food Interactions

Do foods change how 5‑FU works?

No specific food‑drug restrictions are required for systemic 5‑FU as with some oral chemotherapies, but maintaining adequate nutrition and hydration during cycles is important.

Alcohol has no established pharmacokinetic interaction but may worsen mucosal or hepatic adverse effects during treatment.

Drug Combinations To Avoid

Which medicines raise particular concern?

Fluorouracil can potentiate warfarin anticoagulation, so INR should be monitored closely when both agents are used.

Increased 5‑FU toxicity has been reported with concomitant allopurinol and metronidazole; clinicians should avoid these combinations where possible or monitor intensively.

Co‑administration with other myelosuppressive agents requires dose modification and blood monitoring.

DPYD deficiency dramatically increases risk of severe interactions and toxicity; genotyping and e‑prescribing alerts are increasingly recommended in UK and EU oncology practice.

Patient Experience Analysis

Survey Data

Want to know how patients actually cope with treatment?

Dermatology survey datasets from 2020–2024 show high satisfaction with topical 5‑FU effectiveness despite frequent local adverse effects.

Approximately 70–85% of patients expect visible inflammation and 60–75% complete the prescribed topical course in real‑world audits.

Systemic oncology patients generally accept the toxicity profile of 5‑FU when outcomes are clear, and adherence to infusion schedules depends on active management of nausea, mucositis and neutropenia.

Forum Trends

Curious what patients say on forums?

UK online forums frequently use the phrase “worse before better” to describe the appearance during topical courses, and patients give practical tips on sun avoidance and planning for social or work impact.

Systemic therapy discussions emphasise the value of DPYD testing, antiemetic regimens and careful anticoagulant monitoring for those on warfarin.

Distribution & Pricing Landscape

Wondering how 5‑FU gets to clinic shelves and what it costs?

Multiple global manufacturers supply the UK market, including Teva, Mylan (Viatris), Sandoz, Pfizer and Medac, alongside hospital procurement of generics.

Injectable vials are typically stocked by hospital trusts and oncology units, while topical tubes are dispensed by dermatology clinics and community pharmacies on prescription.

Topical and IV 5‑FU are prescription‑only and generally reimbursed under NHS formularies where clinically indicated, but local tendering determines brand choice and cost.

Market trends include ongoing generic competition, occasional supply pressure for sterile injectables and interest in single‑use vials for safety.

In our online pharmacy, fluorouracil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table (Descriptive)

Looking for other ways to treat AK or systemic disease?

Capecitabine (Xeloda) is an oral prodrug of 5‑FU used systemically for colorectal and breast cancers and offers the convenience of oral dosing with a similar toxicity profile.

Imiquimod is a topical immune‑response modifier used for AK and superficial BCC; it may be less inflammatory for some patients but can have lower clearance in comparisons.

Photodynamic therapy (PDT) is effective for field cancerisation with faster cosmetic recovery but requires clinic access and equipment.

Cryotherapy is lesion‑directed and quick but is inferior for treating field change and preventing recurrence.

Pros And Cons

Which choice suits which patient?

Topical 5‑FU gives high clearance rates with a predictable inflammatory course and minimal systemic absorption, making it a first‑line field therapy for many AK patients.

Capecitabine provides systemic treatment without infusion but needs adherence and monitoring for hand–foot syndrome and DPYD considerations similar to 5‑FU.

Imiquimod and PDT suit patients prioritising cosmesis or who poorly tolerate topical inflammation.

Selection depends on lesion type, patient comorbidity, and local NHS pathways.

Regulatory Status

UK Specifics

Want to know the legal and policy context in the UK?

Fluorouracil is prescription‑only in the UK and is supplied under MHRA regulation, with topical and injectable formulations listed on NHS formularies in many Trusts.

DPYD genotyping and e‑prescribing safety alerts are increasingly standard practice in UK oncology for systemic high‑dose regimens.

Clinicians should follow local Trust guidance for formulary selections and procurement.

International Notes

How does UK regulation sit with wider approvals?

The FDA recognises topical and IV use in the US and EMA approvals exist under various national procedures in Europe.

The World Health Organization lists fluorouracil as an Essential Medicine.

Manufacturers include Teva, Sandoz, Pfizer and Medac, with legacy brand names such as Adrucil and Efudex known internationally.

Consolidated FAQ

Quick Answers Clinicians And Patients Need

Have quick questions about use, testing and safety?

Is 5‑FU prescription only? Yes — all formulations are prescription only in the UK.

How long is topical treatment? Typically 2–6 weeks, depending on formulation and lesion site.

Do I need DPYD testing? It is recommended for high‑dose systemic regimens and is increasingly used pre‑emptively in the EU/UK.

Can I use 5‑FU in pregnancy? No — it is contraindicated and teratogenic.

How should systemic dosing be monitored? Full blood counts, liver function and renal tests before and during cycles, with dose reductions for organ impairment.

What about interactions? Warfarin potentiation and increased toxicity with allopurinol or metronidazole are clinically important — monitor or avoid combinations.

Where to get it? Prescriptions are supplied via NHS GP, dermatology or oncology clinics and via private supply routes; brand availability varies by Trust.

Visual Guide

Suggested Diagrams And Visual Elements

Want visuals to explain mechanism and what to expect?

Diagram 1: Mechanism‑of‑action flowchart showing 5‑FU → FdUMP and FUTP → thymidylate synthase inhibition and RNA incorporation, with labels for therapeutic effect and toxicity.

Diagram 2: Topical application timeline showing day 0 baseline, week 1 erythema, weeks 2–4 peak reaction, and weeks 6–12 healing and clearance.

Diagram 3: Systemic monitoring checklist — pre‑cycle DPYD genotype, baseline FBC/LFT/renal, on‑treatment weekly counts and toxicity triggers for dose hold or reduction.

Infographic Elements For Patient Leaflets

What should patient leaflets show simply?

“What To Expect” panels: expected skin reactions, when to contact clinic, protective measures including sun avoidance and moisturisers post‑treatment, and safe disposal of topical tubes.

Include a visual sizing guide for treated areas, comparing small lesion versus facial field therapy.

Storage & Transport

Temperature & Handling

Need to store and handle correctly to stay safe?

Injection vials should be stored at 20–25°C and protected from light; do not freeze.

Topical creams and solutions should be stored below 25°C, kept away from heat and moisture, and tubes kept tightly closed.

Transport, Dispensing And Disposal

How are these products moved and disposed of safely?

Temperature‑controlled distribution is preferred for sterile injectables, while topical creams follow standard non‑cold‑chain shipping but should avoid extremes of heat.

Dispensing labels for cytotoxic injectables should include appropriate warnings; topical preparations need clear patient counselling on application and handling.

Disposal of unused injectables and contaminated dressings must follow cytotoxic waste protocols; many community pharmacies accept topical returns for disposal under local policy.

Guidelines For Proper Use

Prescribing Checks And Clinical Governance

What checks should prescribers do before issuing 5‑FU?

Confirm the indication, pregnancy status, hepatic and renal function and a full medication review including warfarin, allopurinol and metronidazole.

Consider DPYD genotyping for systemic high‑dose regimens and document site, surface area and duration for topical prescriptions.

Patient Counselling And Monitoring

How should patients be counselled and followed up?

Explain the expected inflammatory course for topical therapy, wound care, sun avoidance and when to contact clinic for severe symptoms or signs of infection.

Topical treatments usually require a clinic review at the end of the course; systemic therapy requires scheduled blood tests (FBC, LFTs, renal) and toxicity grading with defined dose‑modification rules.

Document brand, strength and batch where relevant and give written aftercare advice to patients.

Delivery Across United Kingdom

Concluding Notes

Still have concerns about starting or prescribing fluorouracil?

Topical 5‑FU remains a highly effective, field‑directed treatment for actinic keratosis with a predictable inflammatory course and good long‑term clearance data from recent meta‑analyses.

Systemic 5‑FU continues to be a cornerstone of many colorectal and gastrointestinal regimens, with DPYD genotyping increasingly used to reduce severe toxicity risk.

Prescribers should follow local Trust formularies, check interactions such as warfarin potentiation, and counsel patients about expected effects and monitoring.

For practical help with brand availability or ordering, community pharmacies and NHS clinics can advise on local supply; private supply options with discreet delivery are used by some patients.

If symptoms of severe toxicity occur, patients should seek immediate medical attention and oncologists should follow local dose‑modification protocols.

Useful comparisons include capecitabine as an oral systemic alternative and imiquimod or PDT for patients prioritising cosmesis or a different tolerability profile.

Wherever possible, document the regimen, expected timeline and aftercare plan in the clinical record and give patients clear written guidance.